Reunion Neuroscience

We are pleased to announce that the first patient has been dosed in our RECONNECT Phase 2 clinical trial of RE104 for the treatment of #postpartumdepression. This marks a significant clinical milestone in the development of our novel, fast-acting, single-dose, #psychedelic therapies to address underserved #mentalhealthdisorders. Learn more: https://bit.ly/3WyXowI

We are thrilled to share our recent article in Psychiatric Times highlighting the clinical development of RE104, a proprietary, serotonergic #psychedelic drug candidate for underserved #mentalhealth disorders, beginning with #postpartumdepression. Thank you to Reunion team members, Robert Alexander, Jasna Hocevar-Trnka, Nathan Bryson, PhD and Beatrix Taylor for their incredible work on this article: https://bit.ly/4eA0eZn

We are excited to announce the publication of the results of preclinical studies in ACS Chemical Neuroscience demonstrating the potential of RE104 for development in depressive disorders. Reunion is advancing RE104, a proprietary, clinical-stage serotonergic #psychedelic drug candidate designed as a safe, fast-acting, short duration therapy for underserved #mentalhealth disorders, beginning with #postpartumdepression. Read the press release: https://bit.ly/3wFJkY4

#MMHWeek2024 is an opportunity to raise awareness of #MaternalMentalHealth as a significant unmet need. Mental health conditions are the leading underlying cause of pregnancy-related death, with preventable deaths accounting for more than 80 percent. In our mission to address the worldwide mental health crisis, Reunion is advancing RE104 for underserved #mentalhealth disorders, beginning with #postpartumdepression.

We are proud to recognize Maternal Mental Health Awareness Week. As part of this year’s #MMHWeek2024 theme, #StorytellingSavesLives, we welcomed two guest speakers who each shared their personal experiences with #PPD. We are passionate about supporting this community as we advance RE104, our proprietary, clinical-stage serotonergic #psychedelic drug candidate designed as a safe, fast-acting, short duration therapy for underserved #mentalhealth disorders, beginning with #postpartumdepression. Learn more: https://bit.ly/3Wj5fyF

Reunion now has the fuel on board to move boldly forward with RE104 into Phase 2 programs in postpartum depression and adjustment disorder in cancer patients. Thank you very much to our top tier investing syndicate for linking arms with us to help bring forward a new and meaningful treatment option to address the worldwide mental health crisis. Onward!

Today, Reunion Neuroscience announced the closing of a $103 million Series A financing co-led by MPM BioImpact and Novo Holdings. The financing will support the RECONNECT Phase 2 clinical trial for RE104 in #postpartumdepression and expansion into other psychiatric indications of high unmet need, including adjustment disorder in #cancer. RE104 is a proprietary, clinical-stage serotonergic psychedelic drug candidate designed as a safe, fast-acting, short duration therapy for underserved #mentalhealth disorders. Read the press release: https://bit.ly/3Wj5fyF

We are excited to announce that the clinical dataset from our Phase 1 study of lead asset, RE104, will be presented in both a podium and poster at the Anxiety and Depression Association of America (ADAA) 2024 Conference taking place April 11-14. RE104 is a proprietary, potential best-in-class, patented prodrug of 4-OH-DiPT, a psilocybin-like compound, being evaluated in patients with underserved mental health disorders, beginning with #PPD. Read the release: https://bit.ly/49seKhH #ADAA2024

Looking forward to SXSW and speaking about new treatments for postpartum depression with Daniel Goldberg Greg Mayes and Melissa Whippo!